PPT-HER2 positive breast carcinoma in the pre and post adjuvant anti-HER-2 therapy era: a

Heather M Gage MD Avanti Rangnekar Robert E Heidel PhD Timothy Panella MD John Bell MD and Amila Orucevic MD PhD The Graduate School of Medicine The Department of Pathology Introduction. Joyce O'Shaughnessy, MD. Kimberly Blackwell, MD. Hope . Rugo. , MD. Reminder: feedback is appreciated. You will be prompted at the end for your feedback.. Updates on Chemotherapy and Other Novel Agents. ASCO-CAP Recommendations For HER2 Testing in Breast Cancer. Criteria For Reporting HER2 Test Results . as Positive. Criteria for Reporting HER2 Test Results . as Negative. Criteria for Reporting Equivocal Results . Dr. . Khaled Abulkhair, PhD. Medical Oncology SCE, Royal College, UK. Ass. Professor of Clinical Oncology. Mansoura University, Egypt. A long Road Searching for optimum Neo-Adjuvant Therapy in Her -2 Positive Breast Cancer. Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings Christy A Russell, MD Keck School of Medicine University of Southern California Metastatic Breast Cancer Antonella Brunello . Kwok-Leung Cheung. Disclosure. No . conflict. of . interests. Learning objectives. To . discuss the pros and cons of adjuvant chemotherapy for breast cancer in the elderly. To . Triple-Negative Breast Cancer. Jamie Carroll, APRN, MSN, CNP. Hope S . Rugo. , MD. . Disclosures for . Ms. Carroll. No financial interests or affiliations to disclose. Disclosures for Dr . Rugo. Contracted Research. Department. of . oncology. . UWM. Epidemiology. Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. . The American Cancer Society has estimated that 279,100 Americans will be diagnosed with breast cancer and 42,690 will die of disease in the United States in 202. Professor of Medicine and Oncology. Karmanos Cancer Institute. Wayne State University. Breast Cancer 101. Biopsy +. Lumpectomy + RT. Mastectomy. SLNBx. ALND (> 3+ micro or macro preop and bx +). Standard, . in Development for . Breast Cancer. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor of Breast Oncology & Professor of Medicine. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor . of Breast Oncology . & Professor of Medicine. Anne Sofie Brems-Eskildsen. Department of Oncology, University Hospital of Aarhus. Guidelines in . Oncology . for ILC follows IDC. ASCO . G. uidelines . for early breast cancer (not mentioned). St. . . . Breast Cancer | . Epidemiology- Australia. Australian Institute of Health and Welfare 2014. ACIM (Australian Cancer Incidence and Mortality) Books. Canberra. AIHW. Overall is the third leading cause of cancer. ishtiaq. . FCPS R3 general surgery unit one UKSO . prof . tariq. . ghaffor. . sb. . . Objectives. Surgical Anatomy. Investigations. Diagnosis. breast. . cancer. . needs. . different. . therapeutic. . strategies. . than. HER-2 . enriched. . tumors. ?. Patrizia Vici. Cleopatra. TDM-1: . EMILIA. Verma. S ESMO 2012. (. Activity. . HR+.